HUM
Humana Inc. NYSE$237.96
Mkt Cap $28.6B
52w Low $163.11
49.2% of range
52w High $315.35
50d MA $189.48
200d MA $240.44
P/E (TTM)
23.7x
EV/EBITDA
13.6x
P/B
1.6x
Debt/Equity
0.7x
ROE
6.1%
P/FCF
82.3x
RSI (14)
—
ATR (14)
—
Beta
0.45
50d MA
$189.48
200d MA
$240.44
Avg Volume
2.0M
About
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transi…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | TNS | 9.97 | 10.31 | +3.4% | 243.12 | -0.1% | -2.7% | -3.9% | — | — | — | — | — |
| Feb 11, 2026 | TNS | -4.00 | -3.96 | +1.0% | 175.40 | -1.5% | +2.0% | +5.0% | +5.5% | +6.7% | +8.6% | -5.7% | — |
| Nov 5, 2025 | TNS | 2.93 | 3.24 | +10.6% | 264.94 | -1.2% | -5.2% | -4.9% | -10.0% | -8.1% | -9.2% | -2.7% | — |
| Jul 30, 2025 | TNS | 5.92 | 6.27 | +5.9% | 261.47 | -0.5% | -4.4% | -5.4% | -5.4% | -2.7% | -1.9% | +16.1% | — |
| Apr 30, 2025 | TNS | 10.07 | 11.58 | +15.0% | 262.24 | +0.7% | -2.4% | -1.4% | -2.1% | -4.0% | -3.5% | -11.1% | — |
| Feb 11, 2025 | TNS | -2.23 | -2.16 | +3.1% | 257.34 | +0.8% | +1.0% | -1.7% | -1.4% | -0.0% | +3.2% | -2.2% | — |
| Oct 30, 2024 | TNS | 3.40 | 4.16 | +22.4% | 266.32 | -3.3% | -3.2% | -2.1% | -4.0% | -2.1% | +8.3% | +11.3% | — |
| Jul 31, 2024 | TNS | 5.85 | 6.96 | +19.0% | 361.61 | -0.1% | -0.7% | +0.6% | -1.5% | -1.8% | -4.4% | -2.0% | — |
| Apr 24, 2024 | TNS | 6.12 | 7.23 | +18.1% | 315.98 | -0.4% | -1.4% | -3.2% | -4.1% | -4.4% | -0.6% | +10.5% | — |
| Jan 25, 2024 | TNS | -0.07 | -0.11 | -57.1% | 355.36 | -0.1% | +1.7% | +3.0% | +6.0% | +6.4% | +5.8% | +1.3% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | TD Cowen | Maintains | Hold → Hold | — | $236.44 | $237.76 | +0.6% | -1.2% | — | — | — | — |
| May 1 | JP Morgan | Maintains | Neutral → Neutral | — | $236.44 | $237.76 | +0.6% | -1.2% | — | — | — | — |
| Apr 30 | Evercore ISI | Maintains | In Line → In Line | — | $243.12 | $242.94 | -0.1% | -2.7% | -3.9% | — | — | — |
| Apr 30 | Guggenheim | Maintains | Buy → Buy | — | $243.12 | $242.94 | -0.1% | -2.7% | -3.9% | — | — | — |
| Apr 30 | UBS | Maintains | Neutral → Neutral | — | $243.12 | $242.94 | -0.1% | -2.7% | -3.9% | — | — | — |
| Apr 30 | Barclays | Maintains | Equal Weight → Equal Weight | — | $243.12 | $242.94 | -0.1% | -2.7% | -3.9% | — | — | — |
| Apr 30 | Truist | Maintains | Hold → Hold | — | $243.12 | $242.94 | -0.1% | -2.7% | -3.9% | — | — | — |
| Apr 30 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $243.12 | $242.94 | -0.1% | -2.7% | -3.9% | — | — | — |
| Apr 13 | Truist | Maintains | Hold → Hold | — | $192.15 | $191.00 | -0.6% | +3.2% | +2.1% | +3.2% | +4.5% | +6.8% |
| Apr 8 | Evercore ISI | Maintains | In Line → In Line | — | $197.15 | $199.47 | +1.2% | +0.6% | +0.1% | -2.5% | +0.5% | -0.5% |
Recent Filings
8-K
Humana Inc. -- 8-K Filing
Humana reported Q1 2026 earnings results, with detailed financial metrics and forward guidance provided during an earnings call to discuss quarterly performance and future expectations.
Apr 29
8-K
Humana Inc. -- 8-K Filing
Humana Inc. filed a current report on Form 8-K, indicating a material event requiring disclosure to shareholders and the SEC.
Apr 20
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The incomplete 8-K disclosure regarding an executive appointment at HCSG or HUM creates uncertainty about leadership changes, potentially signaling internal instability or succession planning complications that investors should monitor closely.
Apr 10
8-K · 1.01
! Medium
Humana Inc. -- 8-K 1.01: Financing / Debt Agreement
Humana secured a $1.0 billion financing agreement with Goldman Sachs, providing capital flexibility for operations, acquisitions, or debt management.
Mar 9
8-K · 7.01
! Medium
Humana Inc. -- 8-K 7.01: Regulation FD Disclosure
Humana will reaffirm its 2026 guidance of at least $8.89 diluted EPS and $9.00 adjusted EPS during investor meetings scheduled through March 31, 2026.
Mar 2
8-K
Humana Inc. -- 8-K Filing
Humana reported fourth-quarter and full-year 2025 financial results, with management providing guidance on future earnings expectations during an investor conference call.
Feb 11
Data updated apr 25, 2026 2:21pm
· Source: massive.com